title: [Sodium-glucose co-transporter 2 inhibitor for diabetes?].
abstract: Following initial expectations, raised by the results of the United Kingdom Prospective Diabetes Study, intervention studies aimed at tight glucose control did not reduce cardiovascular disease. The EMPA-REG OUTCOME, an empagliflozin intervention study in over 7,000 patients with type 2 diabetes mellitus and a history of cardiovascular disease, for the first time showed a rapid reduction in cardiovascular mortality. The diversity in global recruitment centres and level of glucose control during the intervention may limit the generalisability of these promising results in a high-risk population to generally well-controlled Dutch patients.
authors.affiliation: Vrije Universiteit medisch centrum, afd. Epidemiologie en Biostatistiek, Amsterdam.
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Dekker
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005947:Glucose; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D011446:Prospective Studies; D012964:Sodium; D051297:Sodium-Glucose Transporter 2
chemical_list: D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2; D012964:Sodium; D005947:Glucose